AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023

AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023

Source: 
Fierce Pharma
snippet: 

AbbVie is on a hot streak striking patent deals to protect its top drug, Humira. Even as Boehringer Ingelheim has opted to fight the company’s patent claims in court, Pfizer has decided it’s in its own best interest to settle on a late 2023 biosimilar launch date.